Post-exposure prophylaxis: Nirmatrelvir protects family members…

medicine Friday, July 19, 2024 Philadelphia – The antiviral drug nirmatrelvir, which in combination with ritonavir is the preferred oral drug for early treatment of COVID-19, did not protect family members from symptomatic disease in